Kalytera Therapeutics, Inc. Announces Private Placement

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
98
Kalytera Therapeutics, Inc. Announces Private Placement

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan. 23, 2017) -

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS.

Kalytera Therapeutics, Inc. (TSX VENTURE:KALY) (the " Company " or " Kalytera ") is pleased to announce it has entered into an agreement pursuant to which a syndicate of agents (the " Agents ") led by Clarus Securities Inc. (" Clarus "), and including Haywood Securities Inc. and Canaccord Genuity Corp., has agreed to act on behalf of the Company, on a "best efforts" agency basis, in connection with a brokered private placement (the " Offering ") of up to 24,000,000 common shares (each a " Share "), at a price of per Share of $0.50 (the " Offering Price "), for aggregate gross proceeds of up to $12,000,000.

In connection with the services to be performed by the Agents, the Company will pay a cash commission equal to 7.0% of the gross proceeds of the Offering and that number of broker warrants (the " Broker Warrants ") as is equal to 7.0% of the number of Shares issued pursuant to the Offering. Each Broker Warrant shall be exercisable into one Share at the Offering Price for a period of 24 months following closing of the Offering.

The net proceeds of the Offering will be used by the Company for the acquisition of Talent Biotechs Ltd., to complete work required to advance the Talent Biotechs product into Phase 2b clinical testing for FDA purposes, and for general corporate and working capital purposes.

This proposed Offering is subject to receipt of all required regulatory approvals, including the approval of the TSX Venture Exchange, as well as the negotiation and execution of definitive documentation.

The Shares to be issued under the Offering will be offered pursuant to applicable exemptions from the prospectus requirements under applicable securities laws. Closing of the Offering is anticipated to occur on or about February 7, 2017 or such other date as may be agreed to by the Company and Clarus (the " Closing Date "). The securities issued pursuant to the Offering will be subject to a statutory hold period of four months plus one day from the Closing Date in accordance with applicable securities legislation.

About Kalytera Therapeutics

Kalytera Therapeutics, Inc. (" Kalytera ") is pioneering the development of a next generation of cannabinoid therapeutics. Through its proven leadership, drug development expertise, and intellectual property portfolio, Kalytera seeks to establish a leading position in the development of novel cannabinoid medicines for a range of important unmet medical needs.

Kalytera is focused first on developing a new class of proprietary cannabidiol (" CBD ") therapeutics. CBD is a remarkable compound that has shown activity against a number of pharmacological targets. However, there are limitations associated with natural CBD, including its poor oral bioavailability and short half-life. Kalytera is developing innovative CBD formulations and prodrugs in an effort to overcome these limitations, and to target specific disease sites within the body. Kalytera intends to file composition of matter and method of use patents covering its novel inventions, with the goal of limiting future competition.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements

This press release may contain certain forward-looking information and statements ("forward-looking information") within the meaning of applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements relating to the completion of the Offering, the acquisition of Talent Biotechs Ltd. and associated transactions and statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements depending on, among other things, the risks that the parties may not succesfully complete the Offering or the acquisition of Talent Biotechs Ltd. and associated transactions for any reason (including failure to obtain the required approvals or clearances from regulatory authorities) or that the ultimate terms of the Offering, the acquisition of Talent Biotechs Ltd. and associated transactions will differ from those that are currently contemplated. Kalytera undertakes no obligation to comment on analyses, expectations or statements made by third-parties, its securities, or financial or operating results (as applicable). Although Kalytera believes that the expectations reflected in forward-looking information in this press release are reasonable, such forward-looking information has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Kalytera's control. The forward-looking information contained in this press release are expressly qualified by this cautionary statement and are made as of the date hereof. Kalytera disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Kalytera Therapeutics, Inc. Robert Farrell President, COO and CFO (888) 861-2008 info@kalytera.co
Scroll down for more posts ▼

Top 10 Most Recent News Articles

RBI Heads to Morgan Stanley With Plenty to Explain

Updated Category News Views 30

Two executives, one New York stage, and a short calendar gap give Restaurant Brands International a clean chance to address investors without the usual blizzard of quarterly slides. Chief Executive Officer Josh Kobza and Chief Financial Officer Sami Siddiqui are scheduled for a fireside chat at Morgan Stanley's Global Consumer & Retail Conference on December 2, 2026, at...

Continue Reading
Retainers Are the Unflashy Finish to Orthodontic Care

Updated Category News Views 93

A straight smile has an inconvenient habit of remembering where it came from. That is the plainspoken point in Dr. Michael McClain’s discussion of retainers after braces or Invisalign: the dramatic part of orthodontic treatment may be over when appliances come off, but the maintenance phase has barely started. It is not glamorous, and plenty of people probably wish it...

Continue Reading
Gene Editing’s Steady Revenue Engine Is Taking Shape

Updated Category News Views 112

Gene editing is finally starting to look less like a science-fair moonshot and more like a working supply chain. That distinction matters. The latest market estimate puts the global gene editing market at $5.23 billion in 2026 and projects $8.49 billion by 2031, a 10.1% compound annual growth rate. Respectable growth, certainly, but the real investment story is not a...

Continue Reading
FAA Funding Gridlock Raises Aviation Reliability Risk

Updated Category News Views 74

Friday’s radar and communications trouble delivered the sort of warning nobody in aviation can shrug off: the machinery behind the flight board is getting old, fragile, and far too dependent on people improvising around it. Thousands of flights were delayed or canceled when air traffic control facilities became unstable, according to the Southwest Airlines Pilots...

Continue Reading
PepsiCo Locks In Hyatt's 700-Property U.S. Supply Deal

Updated Category News Views 40

A hotel minibar is a lousy place to hunt for glamour, but it is a terrific place to spot durable distribution. PepsiCo has renewed its U.S. food and beverage relationship with Hyatt for 10 years, covering more than 700 properties. Nobody should pretend a hotel contract transforms a company with nearly $94 billion in 2025 revenue. Still, this is the sort of unflashy...

Continue Reading
UTI Faces Fresh Scrutiny After Its Earnings Guidance Miss

Updated Category News Views 25

A Guidance Gap That Cannot Be Shrugged Off A $0.20-per-share hole is a nasty thing to find after management said it could see the road ahead. Universal Technical Institute reported fiscal 2026 diluted earnings per share of $0.60, below the $0.71 to $0.80 range it reaffirmed on May 6. That is at least $0.11 under the low end and roughly 21% below the midpoint. For...

Continue Reading
TNBC Advocate Campaign Targets Gaps in Patient Clarity

Updated Category News Views 52

Triple-negative is a heavy phrase to hand somebody without a map. Tigerlily Foundation and the Breast Cancer Resource Center are trying to close that gap with a national education campaign scheduled to launch publicly on January 11, 2027. The plan is straightforward on paper: train and mobilize 100 patient advocates across the country to explain triple-negative breast...

Continue Reading
JDEnergy's RE+ Push Meets a Grid Hungry for Storage

Updated Category News Views 64

Certification Is Useful, Not a Victory Lap A battery box earning a safety certificate is not usually thrilling stuff, but the timing matters here. On Nov. 19, 2026, JDEnergy laid out its North American storage pitch at RE+ in Las Vegas while electricity demand is getting shoved higher by industrial buildout and AI data centers. Add more variable renewable generation to an...

Continue Reading
Vision Marine's Cash Cleanup Meets a Hard Reality Ahead

Updated Category News Views 117

A boat dealer slashing debt by $27.5 million deserves a nod, even when the rest of the ledger still makes your eyebrows climb. Vision Marine Technologies turned fiscal 2026 into a working-capital cleanup job: inventory came down hard, floor-plan financing nearly vanished, and operating cash flow finally turned positive. For NASDAQ:VMAR, that is real progress. It is not,...

Continue Reading
Titan Center Lease Gives Pocatello Retail Some Teeth

Updated Category News Views 81

A chicken sandwich lease is not usually a redevelopment thesis, yet Titan Center's new Chick-fil-A deal carries more weight than a routine restaurant announcement. Industrial Realty Group has landed a nationally recognized tenant at the entrance to a property with a long, complicated industrial past. In a smaller market, that sort of win can matter. Retail momentum is...

Continue Reading

Top 5 Most Recently Viewed Articles

Health Monitor Network Strengthens Leadership in Data Insights

Updated Category News Views 195

Strategic Appointment in Health Monitor Network Health Monitor Network, a renowned leader in point of care marketing, has taken a significant leap towards enriching its data analytics and research capabilities with the appointment of Lucia Burchell as Senior Vice President, Analytics, Research & Insights. Burchell's role is poised to empower clients by providing profound...

Continue Reading
Empowering Smallholders in Palm Oil for Sustainable Growth

Updated Category News Views 192

Empowering Smallholders in Palm Oil for Sustainable Growth From financing smallholders to regenerating ecosystems and innovating supply chains, the Roundtable on Sustainable Palm Oil (RSPO) has gathered global stakeholders to explore scalable solutions. This annual conference, an important event in the palm oil industry's agenda, aims to accelerate the industry's...

Continue Reading
t'order Welcomes New CTO to Drive Global Expansion Efforts

Updated Category News Views 169

t'order Inc. Appoints New Chief Technology Officer t'order Inc. has made a significant move by appointing Theo Eom as its Chief Technology Officer. With his extensive background in the tech industry, Theo is expected to lead the company in its ambitious plans for growth and innovation in the table-ordering service sector. The Technology Experience of Theo Eom Theo Eom...

Continue Reading
Manasquan Bank Introduces Home Loans for Local Heroes

Updated Category News Views 266

Supporting Our Local Heroes with New Home Lending Programs Manasquan Bank has proudly introduced innovative home lending products specifically designed for the heroes in our community. This initiative encompasses the dedication provided by educators, first responders, and military personnel. Aimed at making homeownership more achievable, these programs illustrate the...

Continue Reading
Netflix's Strategic Moves Drive Subscriber Gains Amid Prices Rise

Updated Category News Views 285

Netflix's Surging Subscriber Growth Through New Releases Netflix Inc. (NASDAQ: NFLX) has seen a notable uptick in its stock as it capitalizes on substantial gains from international markets and successful content releases. Major titles like Squid Game Season 3 and Stranger Things Season 5 have been pivotal in attracting new subscribers and enhancing user engagement....

Continue Reading